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microbiota, namely, the use of prebiotics, probi-
otics, and fecal microbial transplants.4,5,7,8
Prebiotics are defined as a selectively ferment-
ed ingredients that result in specific changes to 
the composition and activity of the gastrointes-
tinal microbiota, and mainly increase the number 
of bifidobacteria, thus conferring a health benefit 
on the host. Prebiotics are nondigestible polysac-
charides that promote the production of short-
chain fatty acids and the growth of beneficial gut 
bacteria, especially Bifidobacterium and Lactoba-
cillus. Substrates accepted as prebiotics include 
fructans (inulin) and fructo-oligosaccharides, ga-
lacto-oligosaccharides, and lactulose. Probiotics 
are defined as live microorganisms that, when ad-
ministered in adequate amounts, confer a health 
benefit on the host. Most currently used probi-
otics belong to bifidobacteria, lactic acid bacte-
ria, most of them phylum Firmicutes, dairy pro-
pionibacteria, yeasts (Saccharo myces boulardii), 
Bacillus, and the gram-negative Escherichia coli 
strain Nissle 1917.6-8
The dietary prebiotics affect total energy in-
take, body weight, peptide YY and glucagon-like 
peptide-1 concentrations, gastric emptying times, 
insulin sensitivity, lipids, and inflammatory mark-
ers and immune function, although their effects 
were contradictory. Dietary prebiotic consump-
tion was found to be associated with subjective 
improvements in satiety and reductions in post-
prandial glucose and insulin concentrations.4,5,9
Probiotic treatment aiming at modifying the 
colonic flora is thought to produce benefit for sev-
eral reasons: 1) the intestinal bacterial flora favors 
the digestion and absorption of nutrients; 2) gut 
microbiota is related to overall immunity of the 
host; and 3) microbiome may alter the synthesis 
of intestinal hormones such as glucagon-like pep-
tide 1 and influences the host metabolism.4,5,8,10,11
Probiotics are able to decrease metabolic en-
dotoxemia by restoring the disrupted intestinal 
mucosal barrier. There is the perspective of using 
new bacterial strains, such as butyrate-producing 
Type 2 diabetes mellitus, a chronic progressive 
metabolic disease, has reached the proportions of 
an epidemic in the past 30 years, with worldwide 
prevalence approaching 400 million people. The 
epidemic is largely secondary to overnutrition 
and sedentary lifestyle, leading to highly preva-
lent overweight and obesity, which contribute to 
the development of type 2 diabetes.1
Patients with metabolic syndrome and abnor-
mal fat distribution, with the expansion of vis-
ceral fat, have elevated plasma proinflammatory 
markers, prothrombotic state, and vascular dys-
function. These abnormalities contribute causal-
ly to the development of metabolic disorders ob-
served in patients with central obesity.2,3
In recent years, considerable evidence has 
been gathered on the effect of gut microbiota 
composition as a potential factor affecting the 
energy balance and contributing to fat accumu-
lation. The gut microbiota are one of the most 
important determinants of meta bolic disorders 
such as obesity, insulin resistance, and type 2 
diabetes with related comorbidities. There is an 
increasing number of studies exploring the ef-
fects of probiotic bacterial strains in the pre-
vention or treatment of metabolic and cardiovas-
cular risk factors.4,5 The gut microbiota is affect-
ed by a complex interaction between the host’s 
genetics and environ ment; however, diet is one 
of the main factors affecting intesti nal bacteri-
al composition.
The “western” diet, rich in saturated/trans fats 
and simple sugars and poor in fibers, is associated 
with the alteration of bacterial population, lead-
ing to disruption of intestinal barrier, activation 
of proinflammatory mechanisms, and metabol-
ic endotoxemia. In consequence, this leads to ex-
cessive internal diffusion of bacterial fragments/
products, which promotes inflammation in key 
insulin-responsive tissues, resulting in insu lin 
resistance.6-8
There are several approaches to modifying 
the colonic flora and manipulating the intestinal 
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analyses on specific species/strains and specific 
combinations.14
Metabolic disorders, such as obesity, diabe-
tes, and cardiovascular disease, are widespread 
in industrialized societies. The concept that ma-
nipulating the gut microbiota, which influenc-
es metabolic diseases to improve host metabo-
lism, has gained a considerable interest in recent 
years. Currently, several potential bacterial spe-
cies have been identified, and novel mechanisms 
of action influencing their beneficial effects have 
been elucidated. The new treatment option is in-
corporation of genetically modified bacteria that 
secrete molecules into the intestinal microbiota 
to provide sustained treatment. The genetically 
modified bacteria are capable of producing suffi-
cient amounts of secreted small molecules to in-
duce significant therapeutic effects on the target 
organ outside the intestinal tract.15
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bacteria and the mu colytic Akkermansia muciniph-
ila, as well as prebiotics to enhance the function-
ality of probiotics.
In the current issue of Pol Arch Med Wewn, 
Kasińska and Drzewoski,12 in their article, as-
sessed the effect of probiotic supplementation on 
selected modifiable cardiometabolic risk factors 
in type 2 diabetes by a meta-analysis of existing 
research. The authors carefully planned the ma-
terial included in the meta-analysis (reviewed ar-
ticles in PubMed, Embase, Cochrane Library, and 
Scopus databases and searched the databases us-
ing the terms “probiotics” and “diabetes”). They 
included only full-text articles published in Eng-
lish on randomized controlled trials (RCTs) in-
cluding adult patients with diagnosed type 2 di-
abetes. Eventually, 8 RCTs involving 438 subjects 
were included in the meta-analysis.
A pooled analysis of 3 RCTs showed a signif-
icant decrease in the level of hemoglobin A1c 
(HbA1c) in diabetic patients consuming probi-
otics compared with those consuming placebo 
(standardized mean difference [SDM], –0.81; con-
fidence interval [CI], –1.33 to –0.29; P = 0.0021) 
and also 3 RCTs demonstrated a significant de-
crease of HOMA-IR after consumption of probi-
otics vs placebo (SMD, –2.10; CI, –3.00 to –1.2, 
P <0.0001; I2 = 82.91%; P = 0.0029 for heteroge-
neity). In the meta-analysis, supplementation 
with probiotics was not found to alter the lipid 
profile or the levels of fasting glucose, insulin, or 
C-reactive protein.
Overall, the results of the meta-analysis are im-
portant for the treatment of patients with type 
2 diabetes. The use of probiotics has been shown 
to significantly improve long-term glycemic con-
trol, measured by HbA1c levels and insulin resis-
tance, assessed by the HOMA-IR. These effects 
could potentially inhibit the progression of the 
disease and hamper the development of its chron-
ic complications. Finally, the use of well-studied 
probiotic species is safe, and they are generally 
well tolerated.13
A meta-analysis allows to combine individual 
small trials to improve the power to detect the 
direction, size, and consistency of an effect. It is 
necessary to use a meta-analysis to synthesize the 
results of RCTs into recommendations for clini-
cians. The results of this meta-analysis are impor-
tant for the treatment of diabetes and prevention 
of macro- and microvascular complications. How-
ever, the main limitation of this meta-analysis is 
a lack of subgroup analysis for specific species/
strains or species combination on metabolic pa-
rameters. The different probiotic species/strains 
used in clinical trials in different doses will like-
ly affect their clinical efficacy in type 2 diabetes 
patients. Therefore, synthesizing the data from 
different interventions may in part be responsi-
ble for the significant heterogeneity observed in 
the current meta-analysis. Some authors recom-
mend that all future meta-analyses of probiotics, 
in any clinical setting, should include subgroup 
